Kiadis Pharma Appoints Dr. Vincent Brichard to its Supervisory Board

Amsterdam, The Netherlands, May 7, 2015 – Kiadis Pharma B.V. (“Kiadis Pharma” or “the Company”), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive immunother­a­py treat­ments, today announces the appoint­ment of Dr. Vincent Brichard as an inde­pen­dent mem­ber of its Supervisory Board.
Dr. Brichard has more than 25 years’ expe­ri­ence in the oncol­o­gy and immunol­o­gy field, includ­ing almost 15 years at GlaxoSmithKline (“GSK”) where he was Senior Vice-President and had respon­si­bil­i­ty for the Immunotherapeutics Business Unit, which cov­ered a broad, inte­grat­ed approach to immunother­a­py – from bench dis­cov­ery through clin­i­cal devel­op­ment and oper­a­tions to reg­u­la­to­ry and com­mer­cial activ­i­ties. In addi­tion to this posi­tion, he served as a mem­ber of the Board of Directors at GSK Biologicals. Dr. Brichard is a physi­cian by train­ing and holds a PhD in tumor immunol­o­gy. He began his aca­d­e­m­ic career at the Ludwig Institute for Cancer Research, Brussels Branch, fol­lowed by posi­tions at the Institut Curie Cancer Center, Paris, and at the University of Louvain, Brussels. He fur­ther holds an MBA from the Harvard Business School.
Manfred Rüdiger, CEO of Kiadis Pharma, com­ment­ed: “We are very pleased to have attract­ed some­one of Dr. Brichard’s cal­iber to the Board. His strong back­ground and suc­cess­ful career in oncol­o­gy and immunol­o­gy will com­ple­ment the Company’s already strong team and net­work. We look for­ward to ben­e­fit­ing from his coun­sel.”
Dr. Vincent Brichard com­ment­ed: “With my back­ground in oncol­o­gy and immunol­o­gy, my work has been focused since 1986 on the appeal­ing project of edu­cat­ing our nat­ur­al defens­es – those that pro­tect us from infec­tious dis­eases – to rec­og­nize and kill can­cer cells. ATIR™ achieved some extreme­ly com­pelling clin­i­cal data and the Phase II study inter­im analy­sis in December demon­strat­ed the drug’s true poten­tial as an adjunc­tive life-sav­ing ther­a­py for blood can­cer patients. I am look­ing for­ward to join­ing the Board and work­ing with the team to devel­op ATIR™ to its full poten­tial.”

Leave a Reply

Your email address will not be published. Required fields are marked *